about
Implication of Complement System and its Regulators in Alzheimer’s DiseaseC1 esterase inhibitor reduces lower extremity ischemia/reperfusion injury and associated lung damage.Recombinant membrane-targeted form of CD59 inhibits the growth of choroidal neovascular complex in mice.Cell membrane modification for rapid display of bi-functional peptides: a novel approach to reduce complement activation.A novel liposome-based therapy to reduce complement-mediated injury in revascularized tissues.Complement and systemic lupus erythematosus.Complement receptor 2-mediated targeting of complement inhibitors to sites of complement activation.Neuronal death in Alzheimer's disease and therapeutic opportunities.The immunobiology of Guillain-Barré syndromes.Progress and Trends in Complement TherapeuticsAntibody-induced arthritis: disease mechanisms and genes involved at the effector phase of arthritis.Recent developments in the understanding and management of paroxysmal nocturnal haemoglobinuria.Prevention of experimental autoimmune myasthenia gravis by rat Crry-Ig: A model agent for long-term complement inhibition in vivoRole of complement and perspectives for intervention in ischemia-reperfusion damage.Immunotherapy of prostate cancer: identification of new treatments and targets for therapy, and role of WAP domain-containing proteins.Bacterial expression and membrane targeting of the rat complement regulator Crry: a new model anticomplement therapeuticAPT070 (mirococept), a membrane-localizing C3 convertase inhibitor, attenuates early human islet allograft damage in vitro and in vivo in a humanized mouse model.Nontransgenic hyperexpression of a complement regulator in donor kidney modulates transplant ischemia/reperfusion damage, acute rejection, and chronic nephropathy.Complement factor H-related hybrid protein deregulates complement in dense deposit disease.APT070 (Mirococept), a membrane-localised complement inhibitor, inhibits inflammatory responses that follow intestinal ischaemia and reperfusion injury.Biological activity, membrane-targeting modification, and crystallization of soluble human decay accelerating factor expressed in E. coli.The renaissance of complement therapeutics.Generation of a recombinant, membrane-targeted form of the complement regulator CD59: activity in vitro and in vivo.Coupling complement regulators to immunoglobulin domains generates effective anti-complement reagents with extended half-life in vivo.
P2860
Q28972502-98B0BEC7-B742-4EA5-8B1D-61E36588F7A4Q31132259-29F1A71B-97F1-4BC9-8873-734747C9C5E0Q33671677-436D664B-B9C5-4A34-A1B7-98220C7AE107Q34166700-BF4150C0-9E2E-40D5-9E41-4692E11AC415Q34423372-56B064CA-90B8-4ADA-BBF4-5CF53A26AE9EQ34731255-D62B1C02-EABC-4C18-B7F1-F52BBFC19DECQ35095565-182D3BA4-8DFE-4BCB-B243-5E2311EA1D48Q35889067-5082C7D5-3CA4-4614-B260-1CE3E9FC0809Q36164122-21F07809-DEB2-439F-B4DE-994C3565179DQ36479278-F21A664E-06A1-4CE4-9094-17D24B5ECACBQ36718541-D2944B9C-1DCF-4D8A-A5F7-DACAAC48DD42Q36780187-4FF2F363-457C-4E19-916F-314C4F54314EQ36947184-DEB83963-614A-44DC-8F6E-A180CF1854D4Q37831329-358FF089-2085-43DC-A63B-65C58EFE6881Q37936540-5E16A7A5-1C53-457B-84D2-9F8C8EF87D32Q38270278-8191354F-21CB-4B10-84E2-AC533313663BQ38411332-6045F369-4042-4FBF-A713-AFD4C0DCE03BQ41090414-AC7D87F1-E64C-40BC-92B8-91D5CFB6FB2BQ41826438-DE1B35B2-DB18-42FF-AC05-C2591C20D0D8Q42121465-BF4F578A-22E4-4154-9673-EDFF26F10EF9Q43095136-E0C8EF6C-B88E-4781-9E45-6320CA68D37FQ47336749-01CF286F-A6A3-48D1-9DCB-483FFC5BFD4EQ53650180-FD34CB15-3F20-49B1-A61A-5E94213288D3Q53666820-A055B4C5-5EA8-426D-AAE0-D2EDBBE345D5
P2860
description
2001 nî lūn-bûn
@nan
2001 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Membrane-targeted complement inhibitors.
@ast
Membrane-targeted complement inhibitors.
@en
Membrane-targeted complement inhibitors.
@nl
type
label
Membrane-targeted complement inhibitors.
@ast
Membrane-targeted complement inhibitors.
@en
Membrane-targeted complement inhibitors.
@nl
prefLabel
Membrane-targeted complement inhibitors.
@ast
Membrane-targeted complement inhibitors.
@en
Membrane-targeted complement inhibitors.
@nl
P1433
P1476
Membrane-targeted complement inhibitors.
@en
P2093
P304
P356
10.1016/S0161-5890(01)00047-5
P577
2001-08-01T00:00:00Z